Published in Pharmacol Ther on January 01, 1983
Successful treatment using gentamicin liposomes of Salmonella dublin infections in mice. Antimicrob Agents Chemother (1990) 1.07
Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother (1985) 1.04
Immunomodulation with liposomes: the immune response elicited by liposomes with entrapped dichloromethylene-diphosphonate and surface-associated antigen or hapten. Immunology (1987) 1.01
Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother (2003) 0.97
Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis. Antimicrob Agents Chemother (1993) 0.90
Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. Antimicrob Agents Chemother (1996) 0.88
Antileishmanial activities of stearylamine-bearing liposomes. Antimicrob Agents Chemother (2000) 0.87
Beyond oncology--application of HPMA copolymers in non-cancerous diseases. Adv Drug Deliv Rev (2009) 0.86
Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs. Parasitol Res (2002) 0.86
The use of liposomally-entrapped gentamicin in the treatment of bovine Staphylococcus aureus mastitis. Can J Vet Res (1988) 0.84
Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother (1988) 0.83
Differential inhibition of macrophage microbicidal activity by liposomes. Infect Immun (1985) 0.80
Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection. Antimicrob Agents Chemother (1997) 0.80
Interleukin-1beta (IL-1beta) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis. Br J Pharmacol (1999) 0.78
Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. Adv Drug Deliv Rev (2016) 0.75
Nanostructured delivery systems with improved leishmanicidal activity: a critical review. Int J Nanomedicine (2017) 0.75
Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med (2000) 1.98
Interaction of Sindbis virus with liposomal model membranes. J Virol (1975) 1.85
Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci U S A (1978) 1.82
Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten. Biochemistry (1969) 1.75
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol (2003) 1.63
Skin immunization made possible by cholera toxin. Nature (1998) 1.55
Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun (2000) 1.48
Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol (1998) 1.41
Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A (1992) 1.37
A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J Virol (1995) 1.33
Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun (1999) 1.32
Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst (1998) 1.32
Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A. J Immunol (1979) 1.30
Antibodies to cholesterol. Proc Natl Acad Sci U S A (1988) 1.25
Cytotoxic T lymphocytes to Ebola Zaire virus are induced in mice by immunization with liposomes containing lipid A. Vaccine (1999) 1.25
HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol (1998) 1.22
Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother (1986) 1.22
Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug. Life Sci (1978) 1.19
Antibodies to liposomes, phospholipids and phosphate esters. Chem Phys Lipids (1986) 1.16
Binding of diphtheria toxin to phospholipids in liposomes. Proc Natl Acad Sci U S A (1980) 1.16
Lipid A from endotoxin: antigenic activities of purified fractions in liposomes. J Immunol (1979) 1.16
Interactions of lectins with glycolipids in liposomes. Biochem Biophys Res Commun (1977) 1.12
Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol Heart Circ Physiol (2000) 1.12
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res (2003) 1.11
Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. J Immunol (1977) 1.09
Activation of human complement by liposomes: a model for membrane activation of the alternative pathway. J Immunol (1979) 1.08
Interaction of C-reactive protein with liposomes. III. Membrane requirements for binding. J Immunol (1981) 1.06
Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J Infect Dis (1996) 1.05
Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother (1985) 1.04
Comparative properties of four galactosyl lipids as antigens in liposomes. Immunochemistry (1974) 1.04
Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Infect Immun (1988) 1.03
Choleragen-mediated release of trapped glucose from liposomes containing ganglioside GM1. Proc Natl Acad Sci U S A (1976) 1.01
Antibody binding and complement fixation by a liposomal model membrane. Biochemistry (1969) 1.01
Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages. Infect Immun (1992) 1.01
Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen. Vaccine (1995) 1.00
Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine (2001) 0.99
Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil. Adv Drug Deliv Rev (2000) 0.99
Influence of membrane composition on the interaction of a human monoclonal "anti-Forssman" immunoglobulin with liposomes. Biochemistry (1974) 0.99
Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J Immunol (1995) 0.99
Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect Immun (1998) 0.98
Cholesterol-dependent tetanolysin damage to liposomes. Biochim Biophys Acta (1979) 0.98
Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen. Vaccine (1986) 0.97
Principles of transcutaneous immunization using cholera toxin as an adjuvant. Vaccine (1999) 0.96
Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol (2001) 0.96
Liposomes as vehicles for vaccines. Prog Clin Biol Res (1980) 0.96
Advances in vaccine delivery: transcutaneous immunisation. Expert Opin Investig Drugs (1999) 0.95
Interactions of lipid a and liposome-associated lipid A with Limulus polyphemus amoebocytes. Infect Immun (1983) 0.94
Choleragen (cholera toxin): a bacterial lectin. Proc Natl Acad Sci U S A (1979) 0.94
Heterogeneity of lipid A. Rev Infect Dis (1984) 0.93
Liposomes in leishmaniasis: therapeutic effects of antimonial drugs, 8-aminoquinolines, and tetracycline. Life Sci (1980) 0.92
Liposomes as carriers for vaccines. Immunomethods (1994) 0.91
Immune reactivities of antibodies against glycolipids--I. Properties of anti-galactocerebroside antibodies purified by a novel technique of affinity binding to liposomes. Immunochemistry (1977) 0.91
Natural antibodies against phospholipids and liposomes in humans. Biochem Soc Trans (1984) 0.90
Suppression of cytotoxicity of diphtheria toxin by monoclonal antibodies against phosphatidylinositol phosphate. Biophys J (1982) 0.90
Liposomal subunit vaccines: effects of lipid A and aluminum hydroxide on immunogenicity. J Pharm Sci (1996) 0.90
Heterogeneity of lipid A: comparison of lipid A types from different gram-negative bacteria. J Bacteriol (1984) 0.90
Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery. J Pharm Sci (1999) 0.90
Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. Am J Vet Res (1984) 0.90
Phagocytosis of liposomes by macrophages: intracellular fate of liposomal malaria antigen. Biochim Biophys Acta (1991) 0.90
Interactions of C-reactive protein and complement with liposomes. II. Influence of membrane composition. J Immunol (1979) 0.90
Lipid A fractions analyzed by a technique involving thin-layer chromatography and enzyme-linked immunosorbent assay. Eur J Biochem (1984) 0.89
Phosphate-binding specificities of monoclonal antibodies against phosphoinositides in liposomes. Mol Immunol (1984) 0.89
Influence of glycolipids on immune reactions of phospholipid antigens in liposomes. Biochim Biophys Acta (1985) 0.88
Liposomal chemotherapy in visceral leishmaniasis: an ultrastructural study of an intracellular pathway. Z Parasitenkd (1983) 0.88
Mitogenic activities of lipid A and liposome-associated lipid A: effects of epitope density. Rev Infect Dis (1984) 0.87
Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A. Vaccine (1989) 0.87
Enhancement by lipid A of mucosal immunogenicity of liposome-associated cholera toxin. Rev Infect Dis (1984) 0.87
Effects of negatively charged lipids on phagocytosis of liposomes opsonized by complement. Biochim Biophys Acta (1983) 0.87
Studies on the topography of the catalytic site of acetylcholinesterase using polyclonal and monoclonal antibodies. J Neurochem (1990) 0.87
Sporozoite-induced malaria: therapeutic effects of glycolipids in liposomes. Science (1979) 0.87
Effect of the A and B protomers of choleragen on release of trapped glucose from liposomes containing or lacking ganglioside GM1. J Biol Chem (1977) 0.86
Effects of lipid A and liposomes containing lipid A on platelet and fibrinogen production in rabbits. Blood (1980) 0.86
Complement activation in vitro by the red cell substitute, liposome-encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1. Transfusion (1997) 0.85
The preparation and properties of liposomes in the LA and LAC states. Immunochemistry (1971) 0.85
Light-induced leakage of spin label marker from liposomes in the presence of phototoxic phenothiazines. Photochem Photobiol (1976) 0.85
Visualization of peptides derived from liposome-encapsulated proteins in the trans-Golgi area of macrophages. Immunol Lett (1997) 0.85
Induction and detection of antibodies to squalene. J Immunol Methods (2000) 0.85
Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Vaccine (1997) 0.85
Antibodies reactive with liposomal phospholipids are produced during experimental Trypanosoma rhodesiense infections in rabbits. J Immunol (1983) 0.85
Immune damage to liposomes containing lipids from Schistosoma mansoni worms. Proc Soc Exp Biol Med (1974) 0.85
Inhibition of lymphokine-induced macrophage microbicidal activity against Leishmania major by liposomes: characterization of the physicochemical requirements for liposome inhibition. J Immunol (1986) 0.84
Vitamin A in liposomes. Inhibition of complement binding and alteration of membrane structure. Biochim Biophys Acta (1975) 0.84
Antibodies to lipid A: occurrence in humans. Rev Infect Dis (1984) 0.84
Liposomes in leishmaniasis: effects of parasite virulence on treatment of experimental leishmaniasis in hamsters. Ann Trop Med Parasitol (1984) 0.84
Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A. Immunol Lett (1996) 0.83
The malaria merozoite surface: a 140,000 m.w. protein antigenically unrelated to other surface components on Plasmodium knowlesi merozoites. J Immunol (1983) 0.83
Liposomes as model membranes for ligand-receptor interactions: studies with choleragen and glycolipids. Biochemistry (1979) 0.83
Cross-reactions of nucleic acids with monoclonal antibodies to phosphatidylinositol phosphate and cholesterol. Mol Immunol (1989) 0.83
Proteasome inhibitors block the entry of liposome-encapsulated antigens into the classical MHC class I pathway. Immunol Lett (2000) 0.82
Antibodies to phospholipids and liposomes: binding of antibodies to cells. Biochim Biophys Acta (1987) 0.82
Induction of cytolytic and antibody responses using Plasmodium falciparum repeatless circumsporozoite protein encapsulated in liposomes. Vaccine (1993) 0.82
Re: Antibodies to squalene in Gulf War Syndrome. Exp Mol Pathol (2000) 0.81
Membrane lipid composition modulates the binding specificity of a monoclonal antibody against liposomes. Biochim Biophys Acta (1982) 0.81
Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem Biophys Res Commun (1994) 0.81
Interactions of C-reactive protein and complement with liposomes. Proc Natl Acad Sci U S A (1977) 0.80
Lupus anticoagulant activities of murine monoclonal antibodies to liposomal phosphatidylinositol phosphate. Clin Exp Immunol (1987) 0.80
Localization of urinary lactosylceramide in cytoplasmic vesicles of renal tubular cells in homozygous familial hypercholesterolemia. Proc Natl Acad Sci U S A (1983) 0.80
Differential inhibition of macrophage microbicidal activity by liposomes. Infect Immun (1985) 0.80
Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants. Vaccine (1998) 0.79